Inogen, Inc. (INGN)
NASDAQ: INGN · IEX Real-Time Price · USD
7.16
-0.20 (-2.72%)
At close: Apr 15, 2024, 4:00 PM
7.10
-0.06 (-0.84%)
After-hours: Apr 15, 2024, 4:24 PM EDT

Company Description

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally.

Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories.

It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

Inogen, Inc.
Inogen logo
Country United States
Founded 2001
IPO Date Feb 14, 2014
Industry Medical Devices
Sector Healthcare
Employees 834
CEO Kevin R. M. Smith

Contact Details

Address:
859 Ward Drive
Goleta, California 93111
United States
Phone 805-562-0500
Website inogen.com

Stock Details

Ticker Symbol INGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001294133
CUSIP Number 45780L104
ISIN Number US45780L1044
SIC Code 3842

Key Executives

Name Position
Jason Somer Executive Vice President, General Counsel and Corporate Secretary
Dr. Stanislav Glezer M.D., MBA Executive Vice President of Research & Development and Chief Medical Officer
Kevin R. M. Smith President, Chief Executive Officer and Director
Michael J. Bourque Executive Vice President, Chief Financial Officer and Treasurer
Philip Corrin Senior Vice President of Operations and Supply Chain
Jennifer Yi Boyer Executive Vice President and Chief Human Resources Officer
Vijay Paliwal Senior Vice President of Enterprise Enablement
Grgoire Ramade Executive Vice President and Chief Commercial Officer

Latest SEC Filings

Date Type Title
Apr 15, 2024 8-K Current Report
Mar 1, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 1, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 1, 2024 10-K Annual Report
Feb 27, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 24, 2024 8-K Current Report
Jan 24, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals